Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.

Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R; ENCORE1 Study Group.

Clin Pharmacol Ther. 2015 Oct;98(4):406-16. doi: 10.1002/cpt.156. Epub 2015 Jul 14.

2.

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.

ENCORE1 Study Group, Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S, Mohapi L, Crabtree-Ramirez B, Jessen H, Kumar S, Winston A, Lee MP, Belloso W, Cooper DA, Emery S.

Lancet Infect Dis. 2015 Jul;15(7):793-802. doi: 10.1016/S1473-3099(15)70060-5. Epub 2015 Apr 12. Erratum in: Lancet Infect Dis. 2015 Jul;15(7):761.

PMID:
25877963
3.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

4.

Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART.

Winston A, Puls R, Kerr SJ, Duncombe C, Li P, Gill JM, Ramautarsing R, Taylor-Robinson SD, Emery S, Cooper DA; ALTAIR Study Group.

PLoS One. 2015 Feb 27;10(2):e0118608. doi: 10.1371/journal.pone.0118608. eCollection 2015.

5.

Reframing HIV care: putting people at the centre of antiretroviral delivery.

Duncombe C, Rosenblum S, Hellmann N, Holmes C, Wilkinson L, Biot M, Bygrave H, Hoos D, Garnett G.

Trop Med Int Health. 2015 Apr;20(4):430-47. doi: 10.1111/tmi.12460. Epub 2015 Feb 16.

6.

HLA-DRB1454 and predictors of new-onset asthma in HIV-infected Thai children.

Bunupuradah T, Hansudewechakul R, Kosalaraksa P, Ngampiyaskul C, Kanjanavanit S, Wongsawat J, Luesomboon W, Sophonphan J, Puthanakit T, Ruxrungtham K, Shearer WT, Ananworanich J; PREDICT study group.

Clin Immunol. 2015 Mar;157(1):26-9. doi: 10.1016/j.clim.2014.12.006. Epub 2014 Dec 26. No abstract available.

PMID:
25546395
7.

Comparison of adherence monitoring tools and correlation to virologic failure in a pediatric HIV clinical trial.

Intasan J, Bunupuradah T, Vonthanak S, Kosalaraksa P, Hansudewechakul R, Kanjanavanit S, Ngampiyaskul C, Wongsawat J, Luesomboon W, Apornpong T, Kerr S, Ananworanich J, Puthanakit T; PREDICT Study Group.

AIDS Patient Care STDS. 2014 Jun;28(6):296-302. doi: 10.1089/apc.2013.0276.

8.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

9.

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.

ENCORE1 Study Group, Puls R, Amin J, Losso M, Phanuphak P, Nwizu C, Orrell C, Young B, Shahar E, Wolff M, Gazzard B, Read T, Hill A, Cooper DA, Emery S.

Lancet. 2014 Apr 26;383(9927):1474-82. doi: 10.1016/S0140-6736(13)62187-X. Epub 2014 Feb 10. Erratum in: Lancet. 2014 Apr 26;383(9927):1464.

PMID:
24522178
10.

Toward an endgame: finding and engaging people unaware of their HIV-1 infection in treatment and prevention.

Burns DN, DeGruttola V, Pilcher CD, Kretzschmar M, Gordon CM, Flanagan EH, Duncombe C, Cohen MS.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):217-24. doi: 10.1089/AID.2013.0274. Epub 2014 Feb 11. Review.

11.

Antiretroviral treatment interruption and loss to follow-up in two HIV cohorts in Australia and Asia: implications for 'test and treat' prevention strategy.

Guy R, Wand H, McManus H, Vonthanak S, Woolley I, Honda M, Read T, Sirisanthana T, Zhou J, Carr A; Australia HIV Observational Database (AHOD) and Treat Asia HIV Observation Database (TAHOD).

AIDS Patient Care STDS. 2013 Dec;27(12):681-91. doi: 10.1089/apc.2012.0439.

12.

Impact of antiretroviral therapy on quality of life in HIV-infected Southeast Asian children in the PREDICT study.

Bunupuradah T, Kosalaraksa P, Vibol U, Hansudewechakul R, Sophonphan J, Kanjanavanit S, Ngampiyaskul C, Wongsawat J, Luesomboon W, Vonthanak S, Ananworanich J, Ruxrungtham K, Puthanakit T; Predict Study Group.

AIDS Patient Care STDS. 2013 Nov;27(11):596-603. doi: 10.1089/apc.2013.0203.

13.

Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis.

Mayer K, Gazzard B, Zuniga JM, Amico KR, Anderson J, Azad Y, Cairns G, Dedes N, Duncombe C, Fidler SJ, Granich R, Horberg MA, McCormack S, Montaner JS, Rees H, Schackman B, Sow PS; International Association of Physicians in AIDS Care.

J Int Assoc Provid AIDS Care. 2013 May-Jun;12(3):208-16. doi: 10.1177/2325957413475839.

PMID:
23666450
14.

Integrating antiretroviral therapy into antenatal care and maternal and child health settings: a systematic review and meta-analysis.

Suthar AB, Hoos D, Beqiri A, Lorenz-Dehne K, McClure C, Duncombe C.

Bull World Health Organ. 2013 Jan 1;91(1):46-56. doi: 10.2471/BLT.12.107003. Epub 2012 Nov 28. Review.

15.

WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems.

Pal SN, Duncombe C, Falzon D, Olsson S.

Drug Saf. 2013 Feb;36(2):75-81. doi: 10.1007/s40264-012-0014-6.

16.

Treatment 2.0: catalyzing the next phase of treatment, care and support.

Duncombe C, Ball A, Passarelli C, Hirnschall G.

Curr Opin HIV AIDS. 2013 Jan;8(1):4-11. doi: 10.1097/COH.0b013e32835ba7ff. Review.

PMID:
23201857
17.

Determinants of HIV drug resistance and public health implications in low- and middle-income countries.

Bertagnolio S, De Luca A, Vitoria M, Essajee S, Penazzato M, Hong SY, McClure C, Duncombe C, Jordan MR.

Antivir Ther. 2012;17(6):941-53. doi: 10.3851/IMP2320. Epub 2012 Aug 16. Review.

PMID:
22898622
18.

Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy.

Winston A, Duncombe C, Li PC, Gill JM, Kerr SJ, Puls RL, Taylor-Robinson SD, Emery S, Cooper DA; Altair Study Group.

Neuroradiology. 2012 Dec;54(12):1331-9. doi: 10.1007/s00234-012-1061-5. Epub 2012 Jul 7.

PMID:
22772471
19.

Assessing adherence in Thai patients taking combination antiretroviral therapy.

Kerr SJ, Avihingsanon A, Putcharoen O, Chetchotisakd P, Layton M, Ubolyam S, Ruxrungtham K, Cooper DA, Phanuphak P, Duncombe C.

Int J STD AIDS. 2012 Mar;23(3):160-5. doi: 10.1258/ijsa.2009.009152.

PMID:
22581867
20.

Adherence and Risk Behaviour in Patients with HIV Infection Receiving Antiretroviral Therapy in Bangkok.

Clarke A, Kerr S, Honeybrook A, Cooper DA, Avihingsanon A, Duncombe C, Phanuphak P, Ruxrungtham K, Ananworanich J, Kaldor J.

Open Virol J. 2012;6:23-8. doi: 10.2174/1874357901206010023. Epub 2012 Feb 24.

Supplemental Content

Loading ...
Support Center